Published in final edited form as:

Int Immunopharmacol. 2013 October ; 17(2): 260–266. doi:10.1016/j.intimp.2013.05.022.

Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function

Sunil K. Joshi^{*,#} and Mark L. Lang^{*}

^{*}Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104

[#]School of Medical Diagnostic and Translational Sciences, Frank Reidy Research Center of Bioelectronics, Old Dominion University, Norfolk, VA 23508 USA

Abstract

Natural Killer T cells (NKT) represent a group of CD1d-restricted T-lineage cells that provide a functional interface between innate and adaptive immune responses in infectious disease, cancer, allergy and autoimmunity. There have been remarkable advances in understanding the molecular events that underpin NKT development in the thymus and in the complex array of functions in the periphery. Most functional studies have focused on activation of T cell antigen receptors expressed by NKT cells and their responses to CD1d presentation of glycolipid and related antigens. Receiving less attention has been several molecules that are hallmarks of Natural Killer (NK) cells, but nonetheless expressed by NKT cells. These include several activating and inhibitory receptors that may fine-tune NKT development and survival, as well as activation via antigen receptors. Herein, we review the possible roles of the NK1.1 and NKG2D receptors in regulating development and function of NKT cells in health and disease. We suggest that pharmacological alteration of NKT activity should consider the potential complexities commensurate with NK1.1 and NKG2D expression.

Keywords

NKT cells; NK1.1; NKG2D; adaptive immunity; pathogenesis

INTRODUCTION

Natural Killer T cells

Natural Killer T (NKT) cells represent a group of T lineage cells of thymic origin with several features that distinguish them from ‘conventional T cells’ [1]. Mature NKT cells are restricted by the MHC class I-related molecule and express a T cell antigen receptor (TCR)

Correspondence to: School of Medical Diagnostic and Translational Sciences, Frank Reidy Research Center of Bioelectronics, Old Dominion University, 4211 Monarch Way, IRP-2, Suite # 434, Norfolk, VA 23508 USA, Tel: 757-683-3214, Fax: 757-451-1010, skjoshi@odu.edu.

FINANCIAL AND COMPETING INTERESTS DISCLOSURE

Research contributing to the ideas discussed in this article is supported by NIH grant AI078993 (to M.L.L.) and a pilot award (to M.L.L.) under AI062629. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

capable of recognizing lipid-containing antigens (Ags) bound to CD1d. Since the discovery of the marine sponge *Agelas mauritanus*-derived alpha-galactosylceramide CD1d-binding glycolipid (α -GC) [2], numerous synthetic glycolipids have been devised and natural self and foreign CD1d ligands have been discovered [3–7]. Several outstanding structural studies have elucidated the manner in which CD1d binds to various ligands and in some cases how the CD1d ligand complex interacts with the NKT TCR and are described elsewhere [8–12].

NKT cells are broadly grouped into two categories, namely Type I and Type II NKT cells. Murine Type I NKT cells express an invariant V α 14/J α 18 TCR α chain (V α 24/J α 18 in humans) paired with a restricted V β 2, V β 7 or V β 8 repertoire (V β 11 in humans) and are thus termed 'semi-invariant' NKT cells [1,6,7]. These are by far the most well studied subset of NKT cells and are reactive to the α -GC ligand. Recently a Type I-like subset was discovered by the Godfrey laboratory which expresses an invariant V α 10 TCR α chain and is reactive to a glucosylceramide ligand [13].

Type II NKT cells represent a group of CD1d-restricted T lineage cells with variable, likely oligoclonal TCR usage [14–17]. Type II NKT cell subsets have proven quite elusive due to their variable TCR usage meaning that a given CD1d ligand such as myelin-derived sulfatide may only detect a fraction of the Type II NKT population [18,19]. Nonetheless, interest in this subset is growing rapidly and investigators are deepening their understanding of Type II NKT functions in health and disease [16]. The information presented in this review focuses on Type I NKT cells.

The classical model for Type I NKT activation is based upon observations that CD1d⁺ professional APCs present CD1d/foreign ligand complexes to NKT cells which are subsequently activated via engagement and cross-linking of the TCR [1,2,20,21]. Several co-receptors such as ICOS, CD40L and CD28 also regulate TCR signaling in NKT cells [22]. More recently, it was reported that Toll-like receptor (TLR)-stimulated IL-12 production by professional APCs in concert with presentation of self CD1d ligand can potently activate NKT cells [23,24]. Clearly, there are at least two major modes of Type I NKT activation and the relative extent to which they occur in vivo could well be influenced by several factors.

Type I NKT cells regulate adaptive immune responses to pathogens, allergens, self-antigens and tumors. Type I NKT cells can boost cytotoxic T cell responses to tumors [25–27] as well as Ag-specific Ab responses to foreign Ags (including allergens) and associated pathogens [28–35]. Type I NKT cells also appear to regulate autoimmune reactions [36]. In a recent study auto-reactive B cell homeostasis in SLE patients was linked to abnormal NKT function and subject to CD1d-dependent control [37]. Consequently, there is much interest in understanding the molecular events that govern the interaction of Type I NKT cells with other immune cell types [28,38,39].

Natural Killer Cells

Natural Killer (NK) cells should not be confused with NKT cells. NK cells develop in the bone marrow, are of the myeloid lineage, and do not express T cell antigen receptors. NK cells are particularly responsive to virus-infected cells and cancer cells, responding often to target cells that have down-regulated expression of the classical MHC. This is achieved via multiple receptors that govern activation. NK cells exert effector function on target cells, by production of IFN γ and release of perforin from intracellular granules, leading to target cell killing. For a review on NK cells and their receptors, the reader is directed to the outstanding review by Dr. Lanier [40]. The biological functions of NK cells and NKT cells therefore differ but overlap. As we will discuss, the surface receptors that constitute the major modes

of activation of NK cells, may play a supporting role by influencing activation of NKT cells via the TCR.

Natural Killer Cell Receptors Expressed by NKT and NK Cells

The natural killer gene complex (NKC) encodes multiple C-type lectin-like receptors which are responsible for the regulation of development and functions of NK and NKT cells depending on the cellular environment. These include NK1.1, the Ly49 family of proteins, and NKG2D. The balance of expression and engagement of these receptors fine tunes NK activation [40] and it is expected that many of these properties also apply to NKT cells.

NK1.1 (also known as KLRB1C and NKR-P1C), is a type II integral membrane glycoprotein with a C-type lectin domain and is a member of the NKR-P1 family of cell surface receptors [41]. This activating receptor associates with the ITAM-bearing γ -chain adaptor molecule normally associated with Fc receptors. NK1.1 is expressed as a disulfide-linked homodimer on all NK and NKT cells in some strains of mice and is a particularly good marker of these cell types in the C57BL/6 genetic background. NKR-P1 receptors family members (to which NK1.1 belongs) do not engage ligands with an MHC class-I-like fold, but rather interact with C-type lectin-like CLEC2 glycoproteins [41,42]. Although crosslinking of the NK1.1 receptor using an NK1.1-specific mAb (clone PK136) induces NK cell-mediated cytotoxicity and effector cytokine secretion, the *in vivo* functions of NK1.1 and the identity of its ligand(s) remain incompletely understood [43].

NKG2D is encoded by the *KLRK1* gene (killer cell lectin-like receptor subfamily K, member 1) on chromosomes 6 and 12 mouse and human respectively. NKG2D is a C-type lectin-like type-2 trans-membrane glycoprotein expressed as a disulfide linked homo-dimer on the surface of natural killer (NK) cells, NKT cells, CD8⁺ cytotoxic T cells, $\gamma\delta$ T cells, and under certain conditions CD4⁺ T cells [44–47].

NKG2D molecules bind to cell surface glycoproteins of the major histocompatibility complex (MHC) class I family and thereby facilitate detection of stressed cells or cells exhibiting aberrant MHC class I expression. In human, the ligands of NKG2D receptor are MHC class I-related protein A (MICA), MICB, UL-16 binding proteins (ULBP) 1 to 3, and lymphocyte effector cell toxicity-activating ligand (Letal/ULBP4/Raet1E) while in mice NKG2D ligands include retinoic acid early transcript-1 proteins (Rae1 α - ϵ), a minor histocompatibility antigen (H-60), and mouse ULBP-like transcript 1 (Mult-1) [48]. As NKG2D ligands are typically expressed by distressed cells, NKG2D ligands can potentially be used as tumor-specific targets with minimal cross-reaction with normal tissues. Indeed, it has been demonstrated that engineered expression of NKG2D (as TCR complex-associated fusion proteins) can lead to enhanced tumor killing by tumor-specific CD8⁺ T cells [49,50].

We will now discuss how NK1.1 and NKG2D may contribute to the development and functions of Type I NKT cells. Understanding the relationship between these molecules and NKT activation will be valuable in designing therapies that pharmacologically alter the activation of NKT cells.

NK1.1 and NKG2D IN NKT DEVELOPMENT

Impressive progress has been made in understanding the mechanisms regulating NKT cell development and is reviewed elsewhere [51,52]. In brief NKT development is highly dependent on homotypic interactions between CD1d-expressing thymocytes [53,54]. The correct TCR gene arrangement is also required, since deletion of the J α 18 gene segment from the TCR locus blocks development [55]. Other studies have reported that self CD1d binding ligands such as the lysosomal glycosphingolipid isoglobotrihexosylceramide (iGb3)

is required for NKT development, but debate exists regarding how many self-ligands could influence development [56]. In more recent studies, co-receptor molecules such as the SLAM (signaling lymphocytic activation molecule) family members (Slamf1 and Slamf6) have been identified as critical for NKT development [53]. Signaling mediators including MAP Kinases, and Erk target protein Egr2 and transcription factors that include PLZF (promyelocytic leukemia zinc finger), E protein transcription factor HEB, c-Myb, and Hobit (Homologue of Blimp-1 in T cells) regulate NKT development [57–61].

Thymic precursor cells receiving the correct balance of signals differentiate through discreet checkpoints, whereby CD4/CD8 double-positive thymocytes are selected based on CD1d expression [53,54]. NKT precursors (in mouse) then differentiate into CD4 single-positive and CD4/CD8 double-negative cells. CD8 single-positive NKT cells are also found in humans [62]. Expression of NK molecules is acquired relatively late during thymic development with NK1.1 being examined closely than other molecules [63,64].

Nonetheless, up-regulation of other NK markers appears commensurate with NK1.1 expression and thus potential contributions of NKG2D might be inferred from such studies. In elegant studies by the Bendelac and Stein groups respectively, several important findings regarding NK receptors were reported [63,64]. NK1.1 expression was increased after commitment to the CD4 or CD8 subsets and recent thymic emigrants were NK1.1⁺ or had low expression which increased considerably in the periphery over the few days following export. NK1.1⁺ NKT cells were shown to have considerably lower cell division than their NK1.1[−] counterparts, suggesting that they represent a more terminally differentiated subset. NK1.1⁺ cells were also detected in a population of mature NKT cells retained in the thymus [65]. NK1.1 expression is regulated by the Tec family kinase Itk and Itk^{−/−} mice were reported to progressively lose peripheral NKT cells with aging [64]. These findings demonstrate an important contribution of NK molecules in the maintenance of NKT cells in the periphery. A flow cytometric analysis of thymic and peripheral NKT cells from NKG2D^{−/−} mice (kind gift from David H. Raulet, University of California, Berkeley) did not reveal any differences in frequency, number or phenotype as compared to cells derived from C57Bl/6 controls (*Lang and Joshi, unpublished observation*). These findings are consistent with the notion that NK receptors including NK1.1 and NKG2D have little if any role to play in early stages of NKT development. However, more detailed studies on the impact of NKT NK1.1 and NKG2D expression in the periphery with regard to differentiation into distinct functional subsets is warranted. Given the diversity of tissue-expressed NK1.1 and NKG2D ligands in the periphery (Table I), it is possible that select ligand/NK1.1 and ligand/NKG2D pairings can deliver a form of ‘tonic’ but non-mitotic signaling to NKT cells that could promote their survival in the periphery (Figure 1a).

NK1.1 AND NKG2D IN NKT FUNCTION

NK1.1 and NKG2D delineate functional NKT subsets

NKT cells express numerous cell surface receptors that were first identified as markers of Natural Killer (NK) cells. These include NK1.1, NKG2D, and the Ly49 family of proteins [66], the balance of expression and engagement of which may fine tune NKT activation. To assist the reader, Table II shows NKT subsets in mouse and human according to CD4, CD8 and NK1.1 expression. While Table II indicates that NKT function with regard to Th1-, Th2- or Th17-skewed responses can be ascribed to different subsets, it is also worth noting that anatomical location and microenvironment can affect NKT function [67]. Arguably, exposure to diverse NK1.1 and NKG2D ligands in different microenvironments could influence these events.

As discussed earlier, NKT cells express NK receptors including NK1.1 during the later stages of thymic development and expression increases further in the periphery. Increased

expression of these receptors is concomitant with a change in the expression of cytokines following stimulation of the TCR with CD1d/α-GC. Several studies have now confirmed that NK1.1⁺ NKT cells are skewed away from Th2 responses and IL-4 production towards Th1 responses and IFNγ production [52,63,64]. Indeed, NKG2D activation on NKT cells can act synergistically with IL-12 to promote a Th1-skewed response [68]. A subset of CD4⁺NK1.1⁺ NKT cells has also been defined which produces very high concentrations of the pro-inflammatory cytokine IL-17 within a few hours of stimulation [69–72]. IL-17-secreting NKT cells, designated as NKT-17 cells, represent a small subset of the NKT cell populations in the thymus, spleen, liver and lung but is enriched in the peripheral lymph nodes [71]. In contrast, a largely CD4⁺NKG2D⁺ NKT cell subset has been reported to express the IL-25 receptor (IL-25R/IL-17RB) and play a major role in Th2-mediated allergy and airway hyper-reactivity by producing large amounts of IL-4 and IL-13 [73]. These findings collectively reinforce the notion that NK1.1 and NKG2D expression by NKT cells are associated with Th1 rather than Th2 or Th17 responses.

A recent study by Kuylensstierna and co-workers provided the most important demonstration to date that NKG2D is important for NKT cell function [74]. Using primary human NKT cells, the authors established NKG2D expression primarily in the CD4⁺ subset, consistent with findings in mice. NKG2D⁺ NKT cells expressed perforin which localized to the contact site between these cells and NKG2D-ligand-expressing target cells. Furthermore, NKG2D engagement led to degranulation and target cell killing. In further experiments, they demonstrated that NKG2D engagement enhanced TCR-mediated NKT activation (represented in model in Figure 1b). Collectively, this study showed that NKG2D plays two important roles in NKT cells. Firstly, NKG2D directly stimulates NKT effector functions and secondly, it acts as a TCR co-receptor to influence cell activation. Understanding how different NKG2D ligands differentially stimulate these diverse biological outcomes is of considerable interest.

Clinically-relevant observations on NKT-expressed NK receptors

Some clinically-oriented studies have highlighted linkages between NKG2D and NKT function in disease. Consistent with the Kuylensstierna study, Wang and colleagues showed that the NKG2D ligand class MHC class I chain-related molecules (MICs) derived from patients tumors could down-regulate NKT cell NKG2D expression and tumor cell killing in vitro [75]. This perhaps provides one explanation of why NKT cells are functionally compromised in cancer patients [75]. In another study, patients with Type II diabetes were shown to have an increased frequency of NKG2D⁺ NKT cells in the peripheral blood as compared to healthy controls [76]. Early onset SLE was associated with changes in the ratio of activating NKG2D/inhibitory NKG2A receptors in multiple cell types including NKT cells [77]. Th1-skewed NKT cells were also elevated in pre-eclamptic women as compared to those undergoing a healthy pregnancy [78]. Interestingly, in pre-eclamptic patients, expression of NKG2A was decreased on NKG2D⁺ NKT cells, suggesting the balance of critical activating and inhibitory signals was altered [78]. Together, these studies suggest an important role for NKG2D in human NKT cells regulating immunity during a variety of disease conditions.

Interestingly, NKT cell NKG2D, but not NK1.1 may represent a target for bacterial pathogenesis. We reported that anthrax toxin-treated murine NKT cells were functionally anergic, responding poorly to TCR stimulation [79]. In that study NKG2D expression by NKT cells but not NK cells was down-regulated following anthrax toxin treatment. NK1.1 expression was not down-regulated indicating a degree of selectivity of this effect. While the anthrax toxin study did not establish causality, the association between NKG2D expression and TCR function was clear and warrants further investigation. Whether bacterial toxins

impact the immune system in part through effects on intrinsic NKT function or extrinsic function is also of considerable interest.

Effect of NKT NK1.1 and NKG2D on transactivation of other immune cells

As described, NKT cells influence a range of adaptive immune responses to tumors, self-antigens, allergens and pathogens. In order to do this, NKT cells appear to be able to carry out some functions directly (intrinsic function) or to influence the behavior of other immune cell types (extrinsic function). There are several reports in the literature which to describe in their entirety would constitute a separate review article. However, the selected examples described in Table III illustrate some likely extrinsic functions of NKT cells.

Hepatic injury following hepatitis B virus infection of mice was reported to be mediated by the immune response to viral antigens. Disease was mediated at least in part by CD1d-restricted but α -GC non-reactive NKT cells which in turn activated NK cells [80]. Vilarinho and colleagues demonstrated that mAb blockade of NKG2D interaction with its ligands prevented the acute immune response and liver damage in a transgenic mouse expressing HBV envelope proteins on a RAG^{-/-} background [81]. Adoptive transfer of NKG2D-depleted donor splenocytes induced less liver damage than transferred NK-depleted splenocytes or whole mixed splenocytes. This work therefore implicated NKG2D⁺ in the ability of NKT cells (possibly Type II NKT cells) to influence the immunological milieu and thus the complex immune response to HBV.

As referenced in Table III, the Steinman laboratory demonstrated that NKT activation with α -GC was able to boost DC maturation and elicit improved tumor-specific CTL responses [26,82,83]. We therefore generated chimeric mice in which NKT cells were NKG2D⁺ or NKG2D-null. Re-constituted mice were immunized with OVA or OVA plus α -GC before adoptive transfer of CFSE-labeled OVA SIINFEKL peptide-specific OT-1 cells. Subsequent flow cytometry analysis revealed no difference in expansion of the OT-1 cells in the presence of NKG2D⁺ or NKG2D-null NKT cells (Figure 2). This observation was surprising in light of the known Th1-skewing effect of NKG2D⁺ NKT cells, but suggested that NKG2D was dispensable for NKT-enhanced CTL expansion. This result would also suggest that NKT cell NKG2D is not required for NKT-enhanced DC maturation and experiments to test this hypothesis are warranted.

The growing number of available examples therefore illustrate an important point, namely that NK1.1 and NKG2D may influence the ability of NKT cells to alter the activity and behaviors of other immune cell types. More experimentation is required to delineate the circumstances under which this occurs and those in which it does not.

CONCLUSIONS AND REMAINING QUESTIONS

There is a paucity of information on the exact contribution of NK1.1 and NKG2D to NKT cell development, homeostasis and activation. However, the information available indicates that NK1.1 and NKG2D could be of importance in the life of an NKT cell and that these molecules represent potential targets for immune system avoidance by pathogens and for immunotherapy. We therefore feel that investigators should consider the following questions in future studies:

- Does NKG2D expression contribute to homeostasis and maintenance in the periphery?
- Which ligands engage NK1.1 and NKG2D expressed by NKT cells?
- To what extent do NK1.1 and NKG2D signaling interact with TCR signaling and affect intrinsic and extrinsic NKT function?

- Do human and murine NKT cells differentially depend on NK1.1 and NKG2D for function?
- How do NK1.1 and NKG2D work in concert with other NK receptors to control cellular activation?
- How does pharmacological manipulation of NK1.1 and NKG2D activity affect NKT function?

NK1.1 and NKG2D are molecules of pivotal importance in the immune system. It will be of significant interest to determine the contribution of NKT cell NK1.1 and NKG2D to the immune response to pathogens, allergens, tumors and auto-antigens.

Acknowledgments

The authors thanks the various members of the Lang laboratory for their experimental work and insights that have contributed to the hypothesis discussed herein. We thank David Raulet (UC Berkeley, CA) for providing tissues from NKG2D^{-/-} mice.

References

1. Taniguchi M, Harada M, Kojima S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. *Annu Rev Immunol.* 2003; 21:483–513. [PubMed: 12543936]
2. Kawano T, Cui J, Koezuka Y, Taura I, Kaneko Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. *Science.* 1997; 278:1626–1629. [PubMed: 9374463]
3. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. *Nat Immunol.* 2011; 12:966–974. [PubMed: 21892173]
4. Wingender G, Rogers P, Batzer G, Lee MS, Bai D, et al. Invariant NKT cells are required for airway inflammation induced by environmental antigens. *J Exp Med.* 2011; 208:1151–1162. [PubMed: 21624935]
5. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. *Annu Rev Immunol.* 1999; 17:297–329. [PubMed: 10358761]
6. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. *Annu Rev Immunol.* 2005; 23:877–900. [PubMed: 15771592]
7. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. *Annu Rev Immunol.* 2007; 25:297–336. [PubMed: 17150027]
8. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. *J Exp Med.* 2005; 202:1517–1526. [PubMed: 16314439]
9. Adams EJ, Luoma AM. The yin and yang of CD1d recognition. *Nat Immunol.* 2012; 13:814–815. [PubMed: 22910387]
10. Lopez-Sagaseta J, Sibener LV, Kung JE, Gumperz J, Adams EJ. Lysophospholipid presentation by CD1d and recognition by a human Natural Killer T-cell receptor. *EMBO J.* 2012; 31:2047–2059. [PubMed: 22395072]
11. Adams EJ, Lopez-Sagaseta J. The immutable recognition of CD1d. *Immunity.* 2011; 34:281–283. [PubMed: 21435579]
12. Wun KS, Cameron G, Patel O, Pang SS, Pellicci DG, et al. A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells. *Immunity.* 2011; 34:327–339. [PubMed: 21376639]
13. Uldrich AP, Patel O, Cameron G, Pellicci DG, Day EB, et al. A semi-invariant Valpha10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. *Nat Immunol.* 2011; 12:616–623. [PubMed: 21666690]

14. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. *Nat Immunol.* 2012; 13:857–863. [PubMed: 22820603]
15. Rhost S, Lofbom L, Rynmark BM, Pei B, Mansson JE, et al. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. *Eur J Immunol.* 2012
16. Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II natural killer T lymphocytes in health and disease. *Scand J Immunol.* 2012; 76:246–255. [PubMed: 22724893]
17. Patel O, Pellicci DG, Uldrich AP, Sullivan LC, Bhati M, et al. Vbeta2 natural killer T cell antigen receptor-mediated recognition of CD1d-glycolipid antigen. *Proc Natl Acad Sci U S A.* 2011; 108:19007–19012. [PubMed: 22065767]
18. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. *J Exp Med.* 2005; 202:1627–1633. [PubMed: 16365146]
19. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. *J Clin Invest.* 2007; 117:2302–2312. [PubMed: 17641782]
20. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. *Int Immunol.* 1995; 7:1157–1161. [PubMed: 8527413]
21. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, et al. CD1 recognition by mouse NK1+ T lymphocytes. *Science.* 1995; 268:863–865. [PubMed: 7538697]
22. Issazadeh-Navikas S. NKT cell self-reactivity: evolutionary master key of immune homeostasis? *J Mol Cell Biol.* 2012; 4:70–78. [PubMed: 22167750]
23. Brennan PJ, Tatituri RV, Brigl M, Kim EY, Tuli A, et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. *Nat Immunol.* 2011; 12:1202–1211. [PubMed: 22037601]
24. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, et al. Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. *J Exp Med.* 2011; 208:1163–1177. [PubMed: 21555485]
25. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. *Proc Natl Acad Sci U S A.* 2006; 103:11252–11257. [PubMed: 16844772]
26. Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. *Immunol Rev.* 2007; 220:183–198. [PubMed: 17979847]
27. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. *J Immunol.* 2007; 178:2853–2861. [PubMed: 17312129]
28. Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, et al. NK T cells provide lipid antigen-specific cognate help for B cells. *Proc Natl Acad Sci U S A.* 2008; 105:8339–8344. [PubMed: 18550809]
29. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. *Science.* 1999; 283:225–229. [PubMed: 9880256]
30. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, et al. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. *J Immunol.* 2005; 175:3309–3317. [PubMed: 16116223]
31. Lang GA, Exley MA, Lang ML. The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. *Immunology.* 2006; 119:116–125. [PubMed: 16792697]
32. Devera TS, Aye LM, Lang GA, Joshi SK, Ballard JD, et al. CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of *Bacillus anthracis* lethal toxin-neutralizing antibodies. *Infect Immun.* 2010; 78:1610–1617. [PubMed: 20123711]

33. Belperron AA, Dailey CM, Bockenstedt LK. Infection-induced marginal zone B cell production of *Borrelia hermsii*-specific antibody is impaired in the absence of CD1d. *J Immunol.* 2005; 174:5681–5686. [PubMed: 15843569]
34. Kobrynski LJ, Sousa AO, Nahmias AJ, Lee FK. Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cells. *J Immunol.* 2005; 174:1787–1790. [PubMed: 15699104]
35. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, et al. Invariant NKT cells sustain specific B cell responses and memory. *Proc Natl Acad Sci U S A.* 2007; 104:3984–3989. [PubMed: 17360464]
36. Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. *J Exp Med.* 2010; 207:943–952. [PubMed: 20439539]
37. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. *Immunity.* 2012; 36:477–490. [PubMed: 22406267]
38. Lang GA, Devera TS, Lang ML. Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. *Blood.* 2008; 111:2158–2162. [PubMed: 18077787]
39. Joshi SK, Lang GA, Devera TS, Johnson AM, Kovats S, et al. Differential contribution of dendritic cell CD1d to NKT cell-enhanced humoral immunity and CD8+ T cell activation. *J Leukoc Biol.* 2012
40. Lanier LL. NK cell recognition. *Annu Rev Immunol.* 2005; 23:225–274. [PubMed: 15771571]
41. Kuroki K, Furukawa A, Maenaka K. Molecular recognition of paired receptors in the immune system. *Front Microbiol.* 2012; 3:429. [PubMed: 23293633]
42. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKR1 family of natural killer cell receptors. *Nat Immunol.* 2003; 4:801–807. [PubMed: 12858173]
43. Reichlin A, Yokoyama WM. Natural killer cell proliferation induced by anti-NK1.1 and IL-2. *Immunol Cell Biol.* 1998; 76:143–152. [PubMed: 9619484]
44. Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? *Curr Opin Immunol.* 2002; 14:306–311. [PubMed: 11973127]
45. Zafirova B, Wensveen FM, Gulin M, Polic B. Regulation of immune cell function and differentiation by the NKG2D receptor. *Cell Mol Life Sci.* 2011; 68:3519–3529. [PubMed: 21898152]
46. Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. *Proc Natl Acad Sci U S A.* 2005; 102:7641–7646. [PubMed: 15894612]
47. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. *Nat Rev Immunol.* 2007; 7:737–744. [PubMed: 17673918]
48. Obeidy P, Sharland AF. NKG2D and its ligands. *Int J Biochem Cell Biol.* 2009; 41:2364–2367. [PubMed: 19631280]
49. Zhang T, Sentman CL. Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells. *J Immunol.* 2013; 190:2455–2463. [PubMed: 23355740]
50. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. *Cancer Res.* 2011; 71:2066–2076. [PubMed: 21282338]
51. Das R, Sant'Angelo DB, Nichols KE. Transcriptional control of invariant NKT cell development. *Immunol Rev.* 2010; 238:195–215. [PubMed: 20969594]
52. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. *Nat Immunol.* 2010; 11:197–206. [PubMed: 20139988]
53. Griewank K, Borowski C, Rietdijk S, Wang N, Julien A, et al. Homotypic interactions mediated by Slamf1 and Slamf6 receptors control NKT cell lineage development. *Immunity.* 2007; 27:751–762. [PubMed: 18031695]
54. Gapin L, Matsuda JL, Surh CD, Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. *Nat Immunol.* 2001; 2:971–978. [PubMed: 11550008]

55. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. *Science*. 1997; 278:1623–1626. [PubMed: 9374462]
56. Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N, et al. Lysosomal glycosphingolipid recognition by NKT cells. *Science*. 2004; 306:1786–1789. [PubMed: 15539565]
57. Hu T, Gimferrer I, Simmons A, Wiest D, Alberola-Ila J. The Ras/MAPK pathway is required for generation of iNKT cells. *PLoS One*. 2011; 6:e19890. [PubMed: 21572967]
58. Hu T, Simmons A, Yuan J, Bender TP, Alberola-Ila J. The transcription factor c-Myb primes CD4+CD8+ immature thymocytes for selection into the iNKT lineage. *Nat Immunol*. 2010; 11:435–441. [PubMed: 20383148]
59. Kronenberg M, Engel I. On the road: progress in finding the unique pathway of invariant NKT cell differentiation. *Curr Opin Immunol*. 2007; 19:186–193. [PubMed: 17303398]
60. Savage AK, Constantinides MG, Han J, Picard D, Martin E, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. *Immunity*. 2008; 29:391–403. [PubMed: 18703361]
61. Eidson M, Wahlstrom J, Beaulieu AM, Zaidi B, Carsons SE, et al. Altered development of NKT cells, gammadelta T cells, CD8 T cells and NK cells in a PLZF deficient patient. *PLoS One*. 2011; 6:e24441. [PubMed: 21915328]
62. O'Reilly V, Zeng SG, Bricard G, Atzberger A, Hogan AE, et al. Distinct and overlapping effector functions of expanded human CD4+, CD8alpha+ and CD4–CD8alpha– invariant natural killer T cells. *PLoS One*. 2011; 6:e28648. [PubMed: 22174854]
63. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. *Science*. 2002; 296:553–555. [PubMed: 11968185]
64. Gadue P, Stein PL. NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation. *J Immunol*. 2002; 169:2397–2406. [PubMed: 12193707]
65. Berzins SP, McNab FW, Jones CM, Smyth MJ, Godfrey DI. Long-term retention of mature NK1.1+ NKT cells in the thymus. *J Immunol*. 2006; 176:4059–4065. [PubMed: 16547241]
66. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. *Nat Immunol*. 2008; 9:495–502. [PubMed: 18425106]
67. Subleski JJ, Wiltout RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. *J Autoimmun*. 2009; 33:275–281. [PubMed: 19682859]
68. Ortaldo JR, Winkler-Pickett R, Wigginton J, Horner M, Bere EW, et al. Regulation of ITAM-positive receptors: role of IL-12 and IL-18. *Blood*. 2006; 107:1468–1475. [PubMed: 16249390]
69. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4–NK1.1– NKT cell population. *Proc Natl Acad Sci U S A*. 2008; 105:11287–11292. [PubMed: 18685112]
70. Doisne JM, Becourt C, Amniai L, Duarte N, Le Ludeuc JB, et al. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions. *J Immunol*. 2009; 183:2142–2149. [PubMed: 19587013]
71. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. *J Exp Med*. 2007; 204:995–1001. [PubMed: 17470641]
72. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. *J Immunol*. 2008; 180:5167–5171. [PubMed: 18390697]
73. Terashima A, Watarai H, Inoue S, Sekine E, Nakagawa R, et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. *J Exp Med*. 2008; 205:2727–2733. [PubMed: 19015310]
74. Kuylensstierna C, Bjorkstrom NK, Andersson SK, Sahlstrom P, Bosnjak L, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytotoxicity and co-stimulation of activation by CD1d. *Eur J Immunol*. 2011; 41:1913–1923. [PubMed: 21590763]
75. Wang H, Yang D, Xu W, Wang Y, Ruan Z, et al. Tumor-derived soluble MICs impair CD3(+)/CD56(+) NKT-like cell cytotoxicity in cancer patients. *Immunol Lett*. 2008; 120:65–71. [PubMed: 18672004]

76. Guo H, Xu B, Gao L, Sun X, Qu X, et al. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. *Exp Biol Med* (Maywood). 2012; 237:556–562. [PubMed: 22547395]
77. Li WX, Pan HF, Hu JL, Wang CZ, Zhang N, et al. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus. *Clin Rheumatol*. 2010; 29:315–323. [PubMed: 20012119]
78. Miko E, Szereday L, Barakonyi A, Jarkovich A, Varga P, et al. The role of invariant NKT cells in pre-eclampsia. *Am J Reprod Immunol*. 2008; 60:118–126. [PubMed: 18573130]
79. Joshi SK, Lang GA, Larabee JL, Devera TS, Aye LM, et al. Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. *PLoS Pathog*. 2009; 5:e1000588. [PubMed: 19779559]
80. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, et al. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. *Immunity*. 2002; 16:583–594. [PubMed: 11970881]
81. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. *Proc Natl Acad Sci U S A*. 2007; 104:18187–18192. [PubMed: 17991774]
82. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. *J Exp Med*. 2005; 202:1507–1516. [PubMed: 16330814]
83. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. *Nat Immunol*. 2002; 3:867–874. [PubMed: 12154358]
84. Eagle RA, Jafferji I, Barrow AD. Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. *Curr Immunol Rev*. 2009; 5:22–34. [PubMed: 19626129]
85. Lang ML. How do natural killer T cells help B cells? *Expert Rev Vaccines*. 2009; 8:1109–1121. [PubMed: 19627191]
86. Juno JA, Keynan Y, Fowke KR. Invariant NKT Cells: Regulation and Function during Viral Infection. *PLoS Pathog*. 2012; 8:e1002838. [PubMed: 22916008]
87. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. *Nat Rev Immunol*. 2011; 11:131–142. [PubMed: 21267014]
88. Swann JB, Coquet JM, Smyth MJ, Godfrey DI. CD1-restricted T cells and tumor immunity. *Curr Top Microbiol Immunol*. 2007; 314:293–323. [PubMed: 17593666]
89. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? *Nat Rev Immunol*. 2004; 4:231–237. [PubMed: 15039760]
90. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. *J Exp Med*. 2005; 202:1623–1626. [PubMed: 16365145]
91. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. *J Exp Med*. 2002; 195:625–636. [PubMed: 11877485]
92. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. *J Immunol*. 2007; 178:2827–2834. [PubMed: 17312126]
93. Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Nagahira K, et al. Murine NKT cells produce Th17 cytokine interleukin-22. *Cell Immunol*. 2009; 254:81–84. [PubMed: 19010461]
94. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. *J Exp Med*. 2002; 195:637–641. [PubMed: 11877486]
95. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. *J Immunol*. 2003; 171:5140–5147. [PubMed: 14607913]
96. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. *J Exp Med*. 2005; 202:1279–1288. [PubMed: 16275765]

97. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. *J Exp Med.* 2002; 196:119–127. [PubMed: 12093876]
98. Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. *J Exp Med.* 2003; 197:1051–1057. [PubMed: 12695492]
99. Devera TS, Shah HB, Lang GA, Lang ML. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. *Eur J Immunol.* 2008; 38:1001–1011. [PubMed: 18350547]

HIGHLIGHTS

- CD1d-restricted Natural Killer T (NKT) cells are appreciated as an important bridge between innate and adaptive immune responses.
- There is less awareness of how molecules normally expressed by NK cells, but also expressed by NKT cells, regulates NKT development and function.
- The NK1.1 and NKG2D receptors may influence later stages of NKT development, survival in the periphery, intrinsic function, and extrinsic function.

Figure 1. Possible effects of NKG2D engagement on peripheral NKT cells

(a) In this model, tonic signaling provided by tissue-expressed NKG2D ligands could help maintain NKT cells in the periphery (b) NKG2D signaling provided by tissue-expressed NKG2D ligands could potentiate the TCR-driven effector functions of NKT cells.

Figure 2. Potentiation of CD8⁺ T cell expansion by NKG2D-null NKT cells

Mixed bone marrow chimeric mice were generated by engrafting irradiated CD45.1 congenic recipients with donor bone marrow mixtures (a) $\text{Ja.18}^{-/-}$ plus C57Bl/6 or (b) $\text{Ja.18}^{-/-}$ plus $\text{NKG2D}^{-/-}$. Mice were immunized with OVA plus α -GC before adoptive transfer of CFSE-labeled MHC I-restricted (OVA SIINFEKL-specific) OT-1 cells. After 96 hours splenocytes were harvested and analyzed by flow cytometry. Dot plots on top row show re-constituted NKT cells in the mixed chimeras. Dot plots on center row show OT-1 cells detected by SIINFEKL-loaded MHC 1 pentamers. Histograms on lower row represent dilution of CFSE in the OT-1 cells. Immunization with OVA alone or a heterologous Ag did not lead to OT-1 expansion (*not depicted*). $\text{Ja.18}^{-/-}$ refers to mice with a TCR Ja.18 gene segment deletion that lack Type I NKT cells [55]. Data are representative of three mice per group.

Table I**NKG2D ligands**

Shows known ligands that could potentially interact with NKG2D expressed on human and murine NKT cells. MIC (MHC-class I polypeptide-related sequence), ULBP (cytomegalovirus UL-16-binding protein), RAE 1 (Retinoic acid early protein 1), RAET 1 (Retinoic acid early transcript 1), MULT1 (murine UL-16 binding protein-like transcript 1), H60 (minor histocompatibility antigen) [47,48,84]. Definitive ligands have not been identified for NK1.1

	NKG2D Ligands
Mouse	RAE-1 α
	RAE-1 β
	RAE-1 γ
	RAE-1 δ
	RAE-1 ϵ
	H60
	H60a
	H60b
	MULT-1
Human	MICA
	MICB
	ULBP-1/RAET1I
	ULBP-2/RAET1H
	ULBP-3/RAET1N
	ULBP-4/RAET1E
	ULBP-6/RAET1L
	RAET1G

Table II**NKT subsets**

Shows major subsets of NKT cells grouped according to CD4, CD8 and NK1.1 expression in humans and mice.

	Type-1 NKT Subtypes	Cytokine Profile	Ref.
Mouse	CD4 ⁺	T _H 1 (IFN γ /TNF α); T _H 2 (IL-4/IL-10/IL-13)	[52,89–91]
	CD4 ⁺ NK1.1 ⁻	IFN γ ^{LO} /IL-4 ^{HI}	
	CD4 ⁻ NK1.1 ⁺	IFN γ ^{HI} /IL-4 ^{LO}	
	CD4 ⁺ NK1.1 ⁺	IFN γ ^{LO} /IL-4 ^{HI} /IL-13 ^{HI}	
	CD8 ⁺	IFN γ /TNF α	
	CD4 ⁻ CD8 ⁻ (DN)	T _H 1 (IFN γ /TNF α); T _H 2 (IL-4/IL-10/IL-13)	
	CD4 ⁻ NK1.1 ⁻ (NKT-17)	IL-17/IL-21/IL-22	[69,72,73,92,93]
Human	CD4 ⁺ CD8 ⁻	T _H 1 (IFN γ /TNF α) ^{LO} ; T _H 2 (IL-4/IL-10/IL-13) ^{HI}	[62,94]
	CD4 ⁻ CD8 ⁺	T _H 1 (IFN γ /TNF α) ^{HI} ; T _H 2 (IL-4/IL-10/IL-13) ^{LO}	
	CD4 ⁻ CD8 ⁻ (DN)	T _H 1 (IFN γ /TNF α); T _H 2 (IL-4/IL-10/IL-13)	

Table III**NKT extrinsic functions**

Shows selected examples of major immune cell types affected by NKT activation. Specific references to original work are cited in the table. The topics are broadly reviewed in [26,85–88]

Cell Type	Effector Function	Ref.
DC	DC Maturation/IL-12 secretion	[26]
CTL	Augment B16 melanoma killing	[83,95]
NK	Immuno-surveillance against sarcoma	[96,97]
B	Enhanced specific Ab responses	[30–32,35,98,99]
CD4 ⁺ T	Enhancement of T cell responses	[95]